What question did this study set out to answer?

This research aims to improve understanding of how pregnancy affects the metabolism of drugs processed by UGT enzymes.

April 17, 2026Open Access

Physiologically‐based pharmacokinetic modelling of uridine 5′‐diphosphoglucorosultransferase (UGT) substrate drugs in pregnant women

Key Points

This research aims to improve understanding of how pregnancy affects the metabolism of drugs processed by UGT enzymes.
Developed p-PBPK models incorporating changes in UGT enzyme expression during pregnancy
Analyzed UGT1A1, UGT1A4, UGT1A9 activity and assumed no change for UGT2B7
Predicted pharmacokinetics of various UGT-metabolized drugs
Models accurately predicted pharmacokinetics for most UGT-metabolized drugs during pregnancy
Highlights significant changes in phase II metabolism during pregnancy
Findings may guide future drug dose adjustments for pregnant women

Abstract

p-PBPK models that incorporated pregnancy-induced changes in UGT1A1, UGT1A4 and UGT1A9 expression/activity, or assumed no change for UGT2B7, accurately predicted the pharmacokinetics of most UGT-metabolized drugs. These findings enhance our understanding of phase II metabolism during pregnancy and may support dose adjustment for those drugs in the future.

Physiologically‐based pharmacokinetic modelling of uridine 5′‐diphosphoglucorosultransferase (UGT) substrate drugs in pregnant women

Key Points

Abstract

Cite This Study

Also Consider

Also Consider